“`html
CMS Unveils GENEROUS Model to Lower Prescription Drug Costs for medicaid Recipients
Table of Contents
A new initiative from the Centers for Medicare & Medicaid Services (CMS) aims to considerably reduce prescription drug spending within the Medicaid program, potentially impacting millions of Americans.The GENEROUS (generating cost Reductions fOr U.S. Medicaid) model, slated to launch in January 2026, will allow participating states to purchase medications at prices comparable to those paid in other developed nations.
Addressing a Growing Financial Burden
In 2024, gross Medicaid spending on prescription drugs exceeded $100 billion, a $10 billion increase from 2022, according to CMS data. Even after accounting for manufacturer rebates, Medicaid spending still reached $60 billion. This escalating cost poses a substantial challenge to state and federal budgets, and the GENEROUS model represents a proactive step toward financial sustainability.
How GENEROUS Will Work
The voluntary, five-year model builds upon existing programs like the Medicaid Drug Rebate Program (MDRP) and the Cell and Gene Therapy Access Model. Under GENEROUS, participating drug manufacturers will be required to adjust thier prices through supplemental rebates to align with Most Favored Nation (MFN) drug pricing – the prices paid in other countries. States will invoice manufacturers directly for these rebates, with CMS monitoring payment accuracy and sharing in the savings through reductions in the federal share of Medicaid payments.
“The GENEROUS Model will help ensure state Medicaid programs are paying a fair and reasonable price for prescription drugs-furthering our efforts to preserve funds for our most vulnerable,” stated CMS Administrator Mehmet Oz, MD.
A Broader Push for Drug Price Reform
The announcement of the GENEROUS model is part of a larger effort by the current management to address high drug prices in the United States. Recent initiatives include executive orders and agreements with major pharmaceutical companies like Pfizer, AstraZeneca, Novo Nordisk, and Eli Lilly and company. These actions signal a commitment to tackling a long-standing issue that affects both individuals and the healthcare system as a whole.
Negotiating for Better Prices and Standardized Coverage
The model will empower CMS to negotiate prices directly with participating manufacturers. Simultaneously, CMS and these manufacturers will work to establish standardized, transparent coverage criteria for medications. This dual approach aims to ensure both affordability and equitable access to essential treatments.
“Drug prices in the US remain far too high,” said CMS Innovation Center Director Abe Sutton. “GENEROUS aims to ensure that Medicaid pricing will be on par with those in other developed nations.”
Next Steps and State Participation
CMS will soon release a Request for Applications for drug manufacturers interested in participating in the GENEROUS model. Concurrently, the agency will seek letters of intent from state medicaid agencies to gauge interest in joining the pilot program. States that express interest will then have the chance to formally apply and potentially opt into the negotiated terms and prices.
HHS Secretary Robert F. Kennedy, Jr. emphasized the potential impact of the initiative, stating, “Thanks to President Trump’s leadership and Dr.Oz’s bold direction at CMS, we’re expanding access to affordable medicines for millions of Americans.”
The success of the GENEROUS model hinges on widespread participation from both states and
